122
Participants
Start Date
August 31, 2016
Primary Completion Date
June 22, 2022
Study Completion Date
April 10, 2026
18F-Fluoromisonidazole
Correlative studies
Cediranib Maleate
Given PO
Laboratory Biomarker Analysis
Correlative studies
Olaparib
Given PO
Positron Emission Tomography
Correlative studies
VCU Massey Comprehensive Cancer Center, Richmond
Moffitt Cancer Center-International Plaza, Tampa
Moffitt Cancer Center, Tampa
Vanderbilt University/Ingram Cancer Center, Nashville
Wayne State University/Karmanos Cancer Institute, Detroit
Weisberg Cancer Treatment Center, Farmington Hills
M D Anderson Cancer Center, Houston
UC San Diego Moores Cancer Center, La Jolla
UC San Diego Medical Center - Hillcrest, San Diego
UCSF Medical Center-Mount Zion, San Francisco
University of California Davis Comprehensive Cancer Center, Sacramento
Smilow Cancer Center/Yale-New Haven Hospital, New Haven
Yale University, New Haven
Dana-Farber Cancer Institute, Boston
BCCA-Vancouver Cancer Centre, Vancouver
University Health Network-Princess Margaret Hospital, Toronto
Collaborators (1)
AstraZeneca
INDUSTRY
National Cancer Institute (NCI)
NIH